Overview of Periodic Safety Update Reports: Where Have We Reached?

Author(s): Ruchika Sharma, Kamal Kant, Anoop Kumar*.

Journal Name: Applied Clinical Research, Clinical Trials and Regulatory Affairs

Volume 7 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Periodic safety update report (PSUR) is now known as the Periodic Benefit-Risk Evaluation Report (PBRER). In July 2012, as per the new European Legislation, 16 Good Pharmacovigilance Practices (GVP) modules came into effect by replacing Vol 9A guidelines. GVP module VII provides the guidance for the preparation, submission and assessment of PSURs. There are twice as many sections to the new PSUR as compared to ICH E2C (R1) document and Volume 9A PSUR guidelines. The new legislation mainly focuses on benefit-risk assessment of medicinal product and promises much more, but after more than 6 years, how much new lesiglation is able to deliver is still unclear. In the literature, various articles have been published regarding the new Legislation module VII but none of them have highlighted the differences between old and new Legislation, How successful are we? What challenges are we facing? The understanding all these points is the need of the hour for Pharmacovigilance audience which will be helpful to implement the Pharmacovigilance (PV) in a more efficient and effective way. Thus, in this article, we have explained the differences between new and old Legislation and when they come into play. Finally, this article provides a brief examination of current challenges and future perspectives of periodic safety update reporting.

Keywords: PSUR, PBRER, module VII, ADRs, pharmacovigilance, pharmaceutical companies.

[1]
International reporting of periodic drug-safety update summaries: final report of cioms working group II. Geneva: council for international organizations of medical sciences. 1992. Available from: https://cioms. ch/wp-content/uploads/2018/09/cioms-international-reporting-periodic-drug-safety-update-summaries.pdf
[2]
ICH Clinical safety data management: periodic safety update reports for marketed drugs E2C. ICH Expert Working Group. Available from: . https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-2-c-r1-clinical-safety-data-management-periodic-safety-update-reports-marketed-drugs-step-5_en.pdf
[3]
ICH E2C - clinical safety data management: periodic safety update reports for marketed drugs. . [Accessed: 20 August 2016] Available from: http://www.ich. org/cache/compo/276-254-1.html
[4]
European Commission (Sep 2008), volume 9a of the rules governing medicinal products in the European Union . 2008. [Accessed: 19 August 2016] Available from: http://ec.europa.eu/health/files/eudralex/vol-9/ pdf/vol9a_09-2008_en.pdf
[5]
Guideline on good pharmacovigilance practices (GVP) module vii- periodic safety update report (rev 1). European medicines agency and heads of medicines agencies . 2013. [Assessed: 1 August 2016] Available from: http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2013/04/WC500142468.pdf
[6]
ICH guideline ICHE2C (R2), providing postmarket periodic safety reports in the ich e2c(r2) format (periodic benefit-risk evaluation report) . 2013. [Accessed: 22 August 2016] Available from: http://www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm346564.pdf
[7]
Schedule YC. Ministry of health and family welfare Government of India, . January 2005.
[8]
Guideline on the processing of renewals in the centralized procedure. European Medicines Agency . 2012. [Assessed: 24 August 2016] Available from: http://ec.europa.eu/health/files/eudralex/vol-2/2012-06_gpr.pdf
[9]
Good pharmacovigilance practices. European medicines agency. . [Assessed: 24 August 2016] Available from: http://www.ema.europa.eu/ema/index.jsp?curl =pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c
[10]
Periodic safety update report, European medicines agency . 2013. [Assessed: 16 August 2016] Available from: http://www.ema.europa.eu/ema/index.jsp?curl =pages/regulation/document_listing/document_listing_000361.jsp
[11]
Draft guidance on providing postmarket periodic safety reports in the ICH E2C(R2) format (periodic benefit-risk evaluation report). U.S. Department of health and human services food and drug administration . 2013.[Assessed: 19 August 2016] Available from: http://www.fda.gov/downloads/drugs/guidance complianceregulatoryinformation/guidances/ucm3465 64.pdf
[12]
EMA eSubmission gateway and web client.. [Assessed: 2 Sep 2016] Available from: http://esubmission.ema.europa.eu/esubmission.html
[14]
EMA. Outcomes of periodic safety update report single assessments Available from: http://www.ema.eu ropa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000620.jsp&mid=WC0b01ac0580902b8d


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 7
ISSUE: 1
Year: 2020
Page: [4 - 11]
Pages: 8
DOI: 10.2174/2213476X06666190823151514

Article Metrics

PDF: 13
HTML: 6
EPUB: 1
PRC: 5